In humans, a recent study has demonstrated that the SGLT2 inhibitor empagliflozin elicited an adaptive increase of energy intake in patients with T2DM, which caused substantially less weight loss than that expected from the energy dissipated because of glycosuria [12]. Here, SLC5A2 is linked to type 2 diabetes mellitus.